AbbVie’s Juvmo Approval Adds More Fuel For Neuroscience Portfolio Growth
The US FDA approved Juvmo (tavapadon) for Parkinson’s disease, as monotherapy or with levodopa, adding another driver for AbbVie’s second-largest and fastest-growing therapeutic area.
Scrip - September 28, 2026

Mirum Looks To Challenge Gilead’s Hepcludex With HDV Phase III Data Success
With Hepcludex on the market for hepatitis delta less than a year, Mirum is eyeing the market as it succeeds in the first of two Phase III trials for its antibody brelovitug.
Scrip - September 28, 2026

Mimosas For Merck As Drugmaker Inks Deal With SciBrunch For KRAS Inhibitor
The drugmaker is paying up to $2.13bn for the Chinese firm’s preclinical KRAS G12D drug SPR2015, adding to the big pharma’s Phase III KRAS G12C inhibitor, calderasib.
Scrip - September 28, 2026

B7-H3 ADC Field Opens As Merck & Co. Pulls US Filing
The second drug candidate from Merck & Co.’s ADC mega-deal with Daiichi Sankyo has hit a stumbling block with the US FDA, after the agency deemed its BLA insufficient for an accelerated approval. Hopes are now pinned on the IDeate-Lung02 Phase III trial.
Scrip - September 28, 2026

Japan Addresses Non-OTC Legal Gray Area - But It’s Not As Simple As It Looks
Planned law revisions in Japan banning the dispensing of normally prescription drugs without a prescription prompt a lawsuit from pharmacies operating in the currently grey legal area.
Pink Sheet - September 28, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: China’s transforming effect; Novo’s new strategy; Roche’s obesity contender; Amgen’s Sjögren’s win; and potential Chinese blockbusters.
Scrip - September 28, 2026

XVIVO Files Heart Assist Transport PMA, Targets 2027 US Launch
XVIVO has filed a PMA for its Heart Assist Transport, backed by 91.4% one-year survival data from the PRESERVE trial. A 2027 US launch is targeted, with the company also lobbying Congress on Medicare coverage of transplant technology.
Medtech Insight - September 28, 2026

AI-Powered CT Moves From Diagnostic Tool To CAD Care Platform
Global diagnostic imaging major Royal Philips is using partnership approaches to achieve clinical validation of its computed tomography-based integrated care pathway for patients with coronary artery disease.
Medtech Insight - September 28, 2026

California Firm Wins Breakthrough Designation For Stimulant Use Disorder Device
NET Recovery has received FDA Breakthrough Device Designation for its noninvasive stimulation device as an aid in reducing psychostimulant use in adults with stimulant use disorder. The company is planning a pivotal trial of about 500 patients to support a future FDA marketing submission.
Medtech Insight - September 28, 2026

EASD: Abbott, Dexcom Studies Show CGMs Reduce Mortality; Patient Awareness Still Concern
Abbott and Dexcom release data highlighting the benefits of continuous glucose monitoring as the companies push for broader reimbursement.
Medtech Insight - September 28, 2026

Sofinnova Partners Closed $93.4M MD Start IV Fund With Plans To Launch 6 To 8 Start-Ups
Sofinnova Partners closed an oversubscribed (€82m) $93.4m to fund for six to eight medtech companies with a focus on cardiovascular and AI-powered technologies, according to partner Anne Osdoit.
Medtech Insight - September 28, 2026

TikTok To Brands: Demand More From Creators Or Keep Losing Consumer Trust
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026

Coherus Looks To Sell Off Final Biosimilars Assets
After already divesting its major biosimilars product franchises, Coherus Oncology has initiated a process to sell off the remaining assets related to the legacy business after exiting the biosimilars sector last year.
Generics Bulletin - September 28, 2026

US Industry Sees Opportunity In FDA User-Fee Reauthorizations
The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.
Generics Bulletin - September 28, 2026

Stada Builds Its Biosimilars Future With Multi-Product SBP Alliance – Including Pembrolizumab
Stada has advanced its biosimilars interests through a partnership with China’s SBP that includes a proposed pembrolizumab rival to Keytruda – as well as up to three additional molecules – in European and CIS markets, with options for the US and Gulf states.
Generics Bulletin - September 28, 2026

Strategic Intent: Boehringer Ingelheim’s Brian Hilberdink on Launching Into the GLP-1 Era
Boehringer Ingelheim's US Human Pharma president on navigating a major launch cycle, competing in obesity without chasing pounds, and playing the long game as a private company.
In Vivo - September 28, 2026

Is The UK Becoming A Cautionary Tale For Off-Patent Markets?
The UK off-patent sector is showing the strain of a decade of price compression, with over 60% of generic volume now reimbursed at under £1 for a month's supply. Medicines UK chair Paul Burden argues the market has passed the point of sustainability.
In Vivo - September 28, 2026

AI-Powered CT Imaging: New Opportunities For Non-Invasive CAD Diagnosis
Global diagnostic imaging major Royal Philips is using partnership approaches to achieve clinical validation of its computed tomography-based integrated care pathway for patients with coronary artery disease.
In Vivo - September 28, 2026